MMR-deficient, MLH1 methylation positive and Lynch syndrome tumours were significantly less likely to be grade I than MMR-intact tumours (39% mismatch repair-deficient, 31% MLH1 methylation positive, 41% Lynch syndrome (p < 0.01)). Here, MLH1 is linked to Lynch syndrome.